Search

Your search keyword '"DeWeese, Theodore L."' showing total 752 results
Start Over Author "DeWeese, Theodore L."
752 results on '"DeWeese, Theodore L."'

1. Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer

Author

Graham, Mindy K., Wang, Rulin, Chikarmane, Roshan, Abel, Bulouere, Vaghasia, Ajay, Gupta, Anuj, Zheng, Qizhi, Hicks, Jessica, Sysa-Shah, Polina, Pan, Xin, Castagna, Nicole, Liu, Jianyong, Meyers, Jennifer, Skaist, Alyza, Zhang, Yan, Rubenstein, Michael, Schuebel, Kornel, Simons, Brian W., Bieberich, Charles J., Nelson, William G., Lupold, Shawn E., DeWeese, Theodore L., De Marzo, Angelo M., and Yegnasubramanian, Srinivasan

Published
2024
Full Text
View/download PDF

2. Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer

Author

Sutera, Philip, Deek, Matthew P., Deek, Rebecca A., Guler, Ozan Cem, Hurmuz, Pervin, Reyhan, Mehmet, Rowe, Steven, Radwan, Noura, Dipasquale, Shirl, Hrinivich, William T., Lowe, Kathryn, Ren, Lei, Saraiya, Biren, Ennis, Ronald, Hathout, Lara, Mayer, Tina, Deweese, Theodore L., Song, Daniel Y., Kiess, Ana, Oymak, Ezgi, Pienta, Kenneth, Feng, Felix, Pomper, Martin, Ozyigit, Gokhan, Tran, Phuoc T., Onal, Cem, and Phillips, Ryan M.

Published
2024
Full Text
View/download PDF

4. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer

Author

Kishan, Amar U, Steigler, Alison, Denham, James W, Zapatero, Almudena, Guerrero, Araceli, Joseph, David, Maldonado, Xavier, Wong, Jessica K, Stish, Bradley J, Dess, Robert T, Pilar, Avinash, Reddy, Chandana, Wedde, Trude B, Lilleby, Wolfgang A, Fiano, Ryan, Merrick, Gregory S, Stock, Richard G, Demanes, D Jeffrey, Moran, Brian J, Tran, Phuoc T, Martin, Santiago, Martinez-Monge, Rafael, Krauss, Daniel J, Abu-Isa, Eyad I, Pisansky, Thomas M, Choo, C Richard, Song, Daniel Y, Greco, Stephen, Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L, Ross, Ashley E, Ciezki, Jay P, Tilki, Derya, Karnes, R Jeffrey, Tosoian, Jeffrey J, Nickols, Nicholas G, Bhat, Prashant, Shabsovich, David, Juarez, Jesus E, Jiang, Tommy, Ma, T Martin, Xiang, Michael, Philipson, Rebecca, Chang, Albert, Kupelian, Patrick A, Rettig, Matthew B, Feng, Felix Y, Berlin, Alejandro, Tward, Jonathan D, Davis, Brian J, Reiter, Robert E, Steinberg, Michael L, Elashoff, David, Boutros, Paul C, Horwitz, Eric M, Tendulkar, Rahul D, Spratt, Daniel E, and Romero, Tahmineh

Subjects
Cancer, Clinical Research, Prostate Cancer, Urologic Diseases, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Androgen Antagonists, Androgens, Brachytherapy, Data Analysis, Humans, Male, Middle Aged, Prostatic Neoplasms, Retrospective Studies, Oncology and Carcinogenesis, Public Health and Health Services
Abstract

ImportanceRadiotherapy combined with androgen deprivation therapy (ADT) is a standard of care for high-risk prostate cancer. However, the interplay between radiotherapy dose and the required minimum duration of ADT is uncertain.ObjectiveTo determine the specific ADT duration threshold that provides a distant metastasis-free survival (DMFS) benefit in patients with high-risk prostate cancer receiving external beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT).Design, settings, and participantsThis was a cohort study of 3 cohorts assembled from a multicenter retrospective study (2000-2013); a post hoc analysis of the Randomized Androgen Deprivation and Radiotherapy 03/04 (RADAR; 2003-2007) randomized clinical trial (RCT); and a cross-trial comparison of the RADAR vs the Deprivación Androgénica y Radio Terapía (Androgen Deprivation and Radiation Therapy; DART) 01/05 RCT (2005-2010). In all, the study analyzed 1827 patients treated with EBRT and 1108 patients treated with EBRT+BT from the retrospective cohort; 181 treated with EBRT and 203 with EBRT+BT from RADAR; and 91 patients treated with EBRT from DART. The study was conducted from October 15, 2020, to July 1, 2021, and the data analyses, from January 5 to June 15, 2021.ExposuresHigh-dose EBRT or EBRT+BT for an ADT duration determined by patient-physician choice (retrospective) or by randomization (RCTs).Main outcomes and measuresThe primary outcome was DMFS; secondary outcome was overall survival (OS). Natural cubic spline analysis identified minimum thresholds (months).ResultsThis cohort study of 3 studies totaling 3410 men (mean age [SD], 68 [62-74] years; race and ethnicity not collected) with high-risk prostate cancer found a significant interaction between the treatment type (EBRT vs EBRT+BT) and ADT duration (binned to

Published
2022

5. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer

Author

Xiang, Michael, Martin, Ting, Savjani, Ricky, Pollom, Erqi L, Karnes, R Jeffrey, Grogan, Tristan, Wong, Jessica K, Motterle, Giovanni, Tosoian, Jeffrey J, Trock, Bruce J, Klein, Eric A, Stish, Bradley J, Dess, Robert T, Spratt, Daniel E, Pilar, Avinash, Reddy, Chandana, Levin-Epstein, Rebecca, Wedde, Trude B, Lilleby, Wolfgang A, Fiano, Ryan, Merrick, Gregory S, Stock, Richard G, Demanes, D Jeffrey, Moran, Brian J, Huland, Hartwig, Tran, Phuoc T, Martin, Santiago, Martinez-Monge, Rafael, Krauss, Daniel J, Abu-Isa, Eyad I, Alam, Ridwan, Schwen, Zeyad, Pisansky, Thomas M, Choo, C Richard, Song, Daniel Y, Greco, Stephen, Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L, Ross, Ashley E, Ciezki, Jay P, Boutros, Paul C, Nickols, Nicholas G, Bhat, Prashant, Shabsovich, David, Juarez, Jesus E, Chong, Natalie, Kupelian, Patrick A, Rettig, Matthew B, Zaorsky, Nicholas G, Berlin, Alejandro, Tward, Jonathan D, Davis, Brian J, Reiter, Robert E, Steinberg, Michael L, Elashoff, David, Horwitz, Eric M, Tendulkar, Rahul D, Tilki, Derya, Czernin, Johannes, Gafita, Andrei, Romero, Tahmineh, Calais, Jeremie, and Kishan, Amar U

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Biomedical Imaging, Prostate Cancer, Cancer, Clinical Research, Urologic Diseases, Aging, Prevention, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antigens, Surface, Biomarkers, Tumor, Clinical Decision Rules, Follow-Up Studies, Glutamate Carboxypeptidase II, Humans, Male, Middle Aged, Neoplasm Staging, Nomograms, Positron Emission Tomography Computed Tomography, Prognosis, Prostatic Neoplasms, Retrospective Studies, Risk Assessment, SEER Program, Survival Analysis, Biomedical and clinical sciences, Health sciences
Abstract

ImportanceProstate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can detect low-volume, nonlocalized (ie, regional or metastatic) prostate cancer that was occult on conventional imaging. However, the long-term clinical implications of PSMA PET/CT upstaging remain unclear.ObjectivesTo evaluate the prognostic significance of a nomogram that models an individual's risk of nonlocalized upstaging on PSMA PET/CT and to compare its performance with existing risk-stratification tools.Design, setting, and participantsThis cohort study included patients diagnosed with high-risk or very high-risk prostate cancer (ie, prostate-specific antigen [PSA] level >20 ng/mL, Gleason score 8-10, and/or clinical stage T3-T4, without evidence of nodal or metastatic disease by conventional workup) from April 1995 to August 2018. This multinational study was conducted at 15 centers. Data were analyzed from December 2020 to March 2021.ExposuresCurative-intent radical prostatectomy (RP), external beam radiotherapy (EBRT), or EBRT plus brachytherapy (BT), with or without androgen deprivation therapy.Main outcomes and measuresPSMA upstage probability was calculated from a nomogram using the biopsy Gleason score, percentage positive systematic biopsy cores, clinical T category, and PSA level. Biochemical recurrence (BCR), distant metastasis (DM), prostate cancer-specific mortality (PCSM), and overall survival (OS) were analyzed using Fine-Gray and Cox regressions. Model performance was quantified with the concordance (C) index.ResultsOf 5275 patients, the median (IQR) age was 66 (60-72) years; 2883 (55%) were treated with RP, 1669 (32%) with EBRT, and 723 (14%) with EBRT plus BT; median (IQR) PSA level was 10.5 (5.9-23.2) ng/mL; 3987 (76%) had Gleason grade 8 to 10 disease; and 750 (14%) had stage T3 to T4 disease. Median (IQR) follow-up was 5.1 (3.1-7.9) years; 1221 (23%) were followed up for at least 8 years. Overall, 1895 (36%) had BCR, 851 (16%) developed DM, and 242 (5%) died of prostate cancer. PSMA upstage probability was significantly prognostic of all clinical end points, with 8-year C indices of 0.63 (95% CI, 0.61-0.65) for BCR, 0.69 (95% CI, 0.66-0.71) for DM, 0.71 (95% CI, 0.67-0.75) for PCSM, and 0.60 (95% CI, 0.57-0.62) for PCSM (P

Published
2021

6. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer

Author

Philipson, Rebecca G, Romero, Tahmineh, Wong, Jessica K, Stish, Bradley J, Dess, Robert T, Spratt, Daniel E, Pilar, Avinash, Reddy, Chandana, Wedde, Trude B, Lilleby, Wolfgang A, Fiano, Ryan, Merrick, Gregory S, Stock, Richard G, Demanes, D Jeffrey, Moran, Brian J, Braccioforte, Michelle, Tran, Phuoc T, Martin, Santiago, Martinez-Monge, Rafael, Krauss, Daniel J, Abu-Isa, Eyad I, Valle, Luca, Chong, Natalie, Pisansky, Thomas M, Choo, C Richard, Song, Daniel Y, Greco, Stephen, Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L, Ross, Ashley E, Ciezki, Jay P, Tilki, Derya, Karnes, R Jeffrey, Klein, Eric A, Tosoian, Jeffrey J, Boutros, Paul C, Nickols, Nicholas G, Bhat, Prashant, Shabsovich, David, Juarez, Jesus E, Kupelian, Patrick A, Rettig, Matthew B, Berlin, Alejandro, Tward, Jonathan D, Davis, Brian J, Reiter, Robert E, Steinberg, Michael L, Elashoff, David, Horwitz, Eric M, Tendulkar, Rahul D, and Kishan, Amar U

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prevention, Urologic Diseases, Prostate Cancer, Cancer, Clinical Research, Aging, Brachytherapy, Humans, Male, Neoplasm Grading, Prostate, Prostatic Neoplasms, Salvage Therapy, Biochemical recurrence, Brachytherapy boost, EBRT, External beam radiation therapy, High-risk prostate cancer, Prostate cancer, Radiorecurrence, Recurrent prostate cancer, Urology & Nephrology, Clinical sciences
Abstract

The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical course, we evaluated rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM) in a cohort of 978 men with radiorecurrent HRPCa who previously received either external beam radiation therapy (EBRT, n = 654, 67%) or EBRT + brachytherapy (EBRT + BT, n = 324, 33%) across 15 institutions from 1997 to 2015. In men who did not die, median follow-up after treatment was 8.9 yr and median follow-up after biochemical recurrence (BCR) was 3.7 yr. Local and systemic therapy salvage, respectively, were delivered to 21 and 390 men after EBRT, and eight and 103 men after EBRT + BT. Overall, 435 men developed DM, and 248 were detected within 1 yr of BCR. Measured from time of recurrence, 5-yr DM rates were 50% and 34% after EBRT and EBRT + BT, respectively. Measured from BCR, 5-yr PCSM rates were 27% and 29%, respectively. Interval to BCR was independently associated with DM (p

Published
2021

7. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis

Author

Sandler, Kiri A, Cook, Ryan R, Ciezki, Jay P, Ross, Ashley E, Pomerantz, Mark M, Nguyen, Paul L, Shaikh, Talha, Tran, Phuoc T, Stock, Richard G, Merrick, Gregory S, Demanes, David Jeffrey, Spratt, Daniel E, Abu-Isa, Eyad I, Wedde, Trude B, Lilleby, Wolfgang, Krauss, Daniel J, Shaw, Grace K, Alam, Ridwan, Reddy, Chandana A, Song, Daniel Y, Klein, Eric A, Stephenson, Andrew J, Tosoian, Jeffrey J, Hegde, John V, Yoo, Sun Mi, Fiano, Ryan, D'Amico, Anthony V, Nickols, Nicholas G, Aronson, William J, Sadeghi, Ahmad, Greco, Stephen C, Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L, Reiter, Robert E, Said, Jonathan W, Steinberg, Michael L, Horwitz, Eric M, Kupelian, Patrick A, King, Christopher R, and Kishan, Amar U

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Trials and Supportive Activities, Prostate Cancer, Clinical Research, Urologic Diseases, Aging, Aged, Brachytherapy, Hemibody Irradiation, Humans, Male, Neoplasm Grading, Pelvis, Prostate, Prostatic Neoplasms, Retrospective Studies, Survival Rate, Gleason grade group 5, Prostate cancer, Radiation therapy, Whole-pelvis irradiation, Urology & Nephrology, Clinical sciences
Abstract

BackgroundThe role of elective whole-pelvis radiotherapy (WPRT) remains controversial. Few studies have investigated it in Gleason grade group (GG) 5 prostate cancer (PCa), known to have a high risk of nodal metastases.ObjectiveTo assess the impact of WPRT on patients with GG 5 PCa treated with external-beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT).Design, setting, and participantsWe identified 1170 patients with biopsy-proven GG 5 PCa from 11 centers in the United States and one in Norway treated between 2000 and 2013 (734 with EBRT and 436 with EBRT+BT).Outcome measurements and statistical analysisBiochemical recurrence-free survival (bRFS), distant metastasis-free survival (DMFS), and prostate cancer-specific survival (PCSS) were compared using Cox proportional hazards models with propensity score adjustment.Results and limitationsA total of 299 EBRT patients (41%) and 320 EBRT+BT patients (73%) received WPRT. The adjusted 5-yr bRFS rates with WPRT in the EBRT and EBRT+BT groups were 66% and 88%, respectively. Without WPRT, these rates for the EBRT and EBRT+BT groups were 58% and 78%, respectively. The median follow-up was 5.6yr. WPRT was associated with improved bRFS among patients treated with EBRT+BT (hazard ratio [HR] 0.5, 95% confidence interval [CI] 0.2-0.9, p=0.02), but no evidence for improvement was found in those treated with EBRT (HR 0.8, 95% CI 0.6-1.2, p=0.4). WPRT was not significantly associated with improved DMFS or PCSS in the EBRT group (HR 1.1, 95% CI 0.7-1.7, p=0.8 for DMFS and HR 0.7, 95% CI 0.4-1.1, p=0.1 for PCSS), or in the EBRT+BT group (HR 0.6, 95% CI 0.3-1.4, p=0.2 for DMFS and HR 0.5 95% CI 0.2-1.2, p=0.1 for PCSS).ConclusionsWPRT was not associated with improved PCSS or DMFS in patients with GG 5 PCa who received either EBRT or EBRT+BT. However, WPRT was associated with a significant improvement in bRFS among patients receiving EBRT+BT. Strategies to optimize WPRT, potentially with the use of advanced imaging techniques to identify occult nodal disease, are warranted.Patient summaryWhen men with a high Gleason grade prostate cancer receive radiation with external radiation and brachytherapy, the addition of radiation to the pelvis results in a longer duration of prostate-specific antigen control. However, we did not find a difference in their survival from prostate cancer or in their survival without metastatic disease. We also did not find a benefit for radiation to the pelvis in men who received radiation without brachytherapy.

Published
2020

9. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis

Author

Patel, Sagar A., Ma, Ting Martin, Wong, Jessica K., Stish, Bradley J., Dess, Robert T., Pilar, Avinash, Reddy, Chandana, Wedde, Trude B., Lilleby, Wolfgang A., Fiano, Ryan, Merrick, Gregory S., Stock, Richard G., Demanes, D. Jeffrey, Moran, Brian J., Tran, Phuoc T., Krauss, Daniel J., Abu-Isa, Eyad I., Pisansky, Thomas M., Choo, C. Richard, Song, Daniel Y., Greco, Stephen, Deville, Curtiland, DeWeese, Theodore L., Tilki, Derya, Ciezki, Jay P., Karnes, R. Jeffrey, Nickols, Nicholas G., Rettig, Matthew B., Feng, Felix Y., Berlin, Alejandro, Tward, Jonathan D., Davis, Brian J., Reiter, Robert E., Boutros, Paul C., Romero, Tahmineh, Horwitz, Eric M., Tendulkar, Rahul D., Steinberg, Michael L., Spratt, Daniel E., Xiang, Michael, and Kishan, Amar U.

Published
2023
Full Text
View/download PDF

10. Prostate-specific membrane antigen PET response associates with metastasis-free survival following stereotactic ablative radiation in oligometastatic prostate cancer

Author

Sutera, Philip, primary, Deek, Matthew P., additional, Deek, Rebecca A., additional, Guler, Ozan Cem, additional, Hurmuz, Pervin, additional, Reyhan, Mehmet, additional, Rowe, Steven, additional, Radwan, Noura, additional, Dipasquale, Shirl, additional, Hrinivich, William T., additional, Lowe, Kathryn, additional, Ren, Lei, additional, Saraiya, Biren, additional, Ennis, Ronald, additional, Hathout, Lara, additional, Mayer, Tina, additional, Deweese, Theodore L., additional, Song, Daniel Y., additional, Kiess, Ana, additional, Oymak, Ezgi, additional, Pienta, Kenneth, additional, Feng, Felix, additional, Pomper, Martin, additional, Ozyigit, Gokhan, additional, Tran, Phuoc T., additional, Onal, Cem, additional, and Phillips, Ryan M., additional

Published
2024
Full Text
View/download PDF

11. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer

Author

Deek, Matthew P., Taparra, Kekoa, Phillips, Ryan, Velho, Pedro Isaacsson, Gao, Robert W., Deville, Curtiland, Song, Daniel Y., Greco, Stephen, Carducci, Michael, Eisenberger, Mario, DeWeese, Theodore L., Denmeade, Samuel, Pienta, Kenneth, Paller, Channing J., Antonarakis, Emmanuel S., Olivier, Kenneth R., Park, Sean S., Tran, Phuoc T., and Stish, Bradley J.

Published
2021
Full Text
View/download PDF

13. Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer

Author

Deek, Matthew P., Taparra, Kekoa, Dao, Dyda, Chan, Luanna, Phillips, Ryan, Gao, Robert W., Kwon, Eugene D., Deville, Curtiland, Song, Daniel Y., Greco, Stephen, Carducci, Michael A., Eisenberger, Mario, DeWeese, Theodore L., Denmeade, Samuel, Pienta, Kenneth, Paller, Channing J., Antonarakis, Emmanuel S., Olivier, Kenneth R., Park, Sean S., Stish, Bradley J., and Tran, Phuoc T.

Published
2021
Full Text
View/download PDF

18. Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment

Author

Moyer, C. Leigh, Phillips, Ryan, Deek, Matthew P., Radwan, Noura, Ross, Ashley E., Antonarakis, Emmanuel S., Reyes, Diane, Wright, Jean, Terezakis, Stephanie A., Song, Daniel Y., DeVille, Curtiland, Walsh, Patrick C., DeWeese, Theodore L., Carducci, Michael, Schaeffer, Edward M., Pienta, Kenneth J., Eisenberger, Mario, and Tran, Phuoc T.

Published
2019
Full Text
View/download PDF

21. Arrested Agonist Paradigm For Selective Radiosensitization of Prostate Cancer

Author

Coulter, Jonathan B., primary, Haffner, Michael, additional, Zhang, Yonggang, additional, Zhou, Haoming, additional, Pham, Minh-Tam Nguyen, additional, Chen, Jiayu, additional, Chikarmane, Roshan, additional, Mishra, Alok, additional, Mehl, Maire S., additional, Kazibwe, Stella, additional, Choi, Kirsten, additional, Archey, Ava, additional, Valluri, Sarayu, additional, Lupold, Shawn E, additional, Song, Daniel, additional, De Marzo, Angelo Michael, additional, Nelson, William G., additional, DeWeese, Theodore L., additional, and Yegnasubramanian, Srinivasan, additional

Published
2023
Full Text
View/download PDF

22. Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer

Author

Graham, Mindy K, primary, Wang, Rulin, additional, Chikarmane, Roshan, additional, Wodu, Bulouere, additional, Vaghasia, Ajay, additional, Gupta, Anuj, additional, Zheng, Qizhi, additional, Hicks, Jessica, additional, Sysa-Shah, Polina, additional, Pan, Xin, additional, Castagna, Nicole, additional, Liu, Jianyong, additional, Meyers, Jennifer, additional, Skaist, Alyza, additional, Zhang, Yan, additional, Schuebel, Kornel, additional, Simons, Brian W, additional, Bieberich, Charles J., additional, Nelson, William G, additional, Lupold, Shawn E., additional, DeWeese, Theodore L, additional, De Marzo, Angelo M, additional, and Yegnasubramanian, Srinivasan, additional

Published
2023
Full Text
View/download PDF

23. Contributors

Author

Abbruzzese, James L., primary, Abdel-Wahab, Omar, additional, Abou-Alfa, Ghassan K., additional, Abrahm, Janet L., additional, Abrams, Jeffrey S., additional, Abramson, Jeremy S., additional, Aisner, Dara L., additional, Alonso-Basanta, Michelle, additional, Anampa, Jesus, additional, Anderson, Megan E., additional, Antonarakis, Emmanuel S., additional, Aplenc, Richard, additional, Appelbaum, Frederick R., additional, Araujo, Luiz H., additional, Asban, Ammar, additional, Ashwood, Edward, additional, Awan, Farrukh T., additional, Aylward, Juliet L., additional, Balar, Arjun V., additional, Balentine, Courtney J., additional, Barta, Stefan K., additional, Bartlett, Nancy, additional, Basen-Engquist, Karen, additional, Beaupin, Lynda Kwon, additional, Berkowitz, Ross S., additional, Berry, Donald A., additional, Bevers, Therese, additional, Boggess, John F., additional, Brahmer, Julie R., additional, Brown, Janet, additional, Brown, Karen, additional, Brown, Powel, additional, Browner, Ilene, additional, Bunn, Paul A., additional, Burns, William R., additional, Byrd, John C., additional, Cadoo, Karen, additional, Carbone, David P., additional, Carter, H. Ballentine, additional, Castillo, Jorge J., additional, Chang, Alfred E., additional, Chang, Eric, additional, Chanock, Stephen J., additional, Chapuy, Claudia I., additional, Chauhan, Vikash P., additional, Chen, Herbert, additional, Chen, Ronald C., additional, Cheung, Nai-Kong V., additional, Choe, Jennifer H., additional, Christian, Michaele C., additional, Cinciripini, Paul M., additional, Clarke, Michael F., additional, Coleman, Robert E., additional, Coleman, Robert L., additional, Coletta, Adriana M., additional, Collins, Jerry M., additional, Connors, Jean M., additional, Cools, Michael, additional, Coombes, Kevin R., additional, Cortes, Jorge, additional, Costa, Mauro W., additional, Covey, Anne, additional, Cowan, Kenneth H., additional, Crane, Christopher H., additional, Crawford, Jeffrey, additional, Crooks, Kristy, additional, Culkin, Daniel J., additional, Czito, Brian G., additional, Dalerba, Piero, additional, Dalmau, Josep, additional, Dang, Mai, additional, D'Angelica, Michael, additional, Davies, Kurtis D., additional, Davis, Myrtle, additional, Dea, Nicolas, additional, De Jesus-Acosta, Ana, additional, DeMarzo, Angelo M., additional, DeWeese, Theodore L., additional, Diehn, Maximilian, additional, Digumarthy, Subba R., additional, Dispenzieri, Angela, additional, Do, Khanh T., additional, Dobrenkov, Konstantin, additional, Dome, Jeffrey S., additional, Doroshow, James H., additional, Dorsey, Jay F., additional, Dubard-Gault, Marianne, additional, DuBois, Steven G., additional, Duda, Dan G., additional, Dunlop, Malcolm, additional, Duska, Linda R., additional, Duvic, Madeleine, additional, El Dika, Imane, additional, El-Serag, Hashem, additional, Engelmann, Jeffrey M., additional, Ettinger, David S., additional, Fashoyin-Aje, Lola A., additional, Fearon, Eric R., additional, Ford, James M., additional, Franklin, Wilbur A., additional, Freer, Phoebe E., additional, Freidlin, Boris, additional, Freifeld, Alison G., additional, Friedlander, Terence W., additional, Friedman, Debra L., additional, Fuller, Arian F., additional, Galluzzi, Lorenzo, additional, Gebhardt, Mark C., additional, George, Daniel J., additional, Geyer, Mark B., additional, Giaccia, Amato J., additional, Gilbert, Mark R., additional, Goldner, Whitney, additional, Goldstein, Donald P., additional, Goodman, Annekathryn, additional, Goodman, Karyn A., additional, Gordon, Kathleen, additional, Graeff-Armas, Laura, additional, Greenstein, Alexander J., additional, Grossman, Stuart A., additional, Grupp, Stephan, additional, Gupta, Arjun, additional, Haider, Irfanullah, additional, Haigentz, Missak, additional, Hainsworth, John D., additional, Haithcock, Benjamin E., additional, Hallemeier, Christopher L., additional, Hanash, Samir, additional, Hanrahan, Aphrothiti J., additional, Harding, James, additional, Harrison, Michael R., additional, Hasham, Muneer G., additional, Hawk, Ernest, additional, Hayman, Jonathan, additional, Heinlen, Jonathan E., additional, Henry, N. Lynn, additional, Herman, Joseph, additional, Hobbs, Brian P., additional, Holen, Ingunn, additional, Horn, Leora, additional, Horowitz, Neil S., additional, Horwitz, Steven M., additional, Houghton, Odette, additional, Howard, Scott C., additional, Hudis, Clifford A., additional, Hunger, Stephen P., additional, Hurria, Arti, additional, Ilson, David H., additional, Im, Annie, additional, Iyer, Gopa, additional, Jaffee, Elizabeth M., additional, Jagsi, Reshma, additional, Jain, Rakesh K., additional, Jarnagin, William, additional, Jatoi, Aminah, additional, Jhingran, Anuja, additional, Johnson, David H., additional, Johnston, Brian, additional, Johnston, Patrick G., additional, Judy, Kevin D., additional, Kachnic, Lisa A., additional, Kaidar-Person, Orit, additional, Kalva, Sanjeeva, additional, Kamin, Deborah Y., additional, Kantarjian, Hagop, additional, Karakousis, Giorgos, additional, Karam-Hage, Maher, additional, Kaskas, Nadine M., additional, Kastan, Michael B., additional, Katabi, Nora, additional, Kaul, Daniel R., additional, Kelley, Scott R., additional, Kemeny, Nancy, additional, Kent, Erin E., additional, Kepp, Oliver, additional, Khagi, Simon, additional, Kilgore, Joshua E., additional, Kim, D. Nathan, additional, Kleinschmidt-DeMasters, Bette K., additional, Korn, Edward L., additional, Kroemer, Guido, additional, Ku, Geoffrey Y., additional, Kummar, Shivaani, additional, Ky, Bonnie, additional, Laheru, Daniel A., additional, Lambert, Paul F., additional, Lawler, Mark, additional, Le-Rademacher, Jennifer G., additional, Lee, John Y.K., additional, Lee, Nancy Y., additional, Lee, Susanna L., additional, Leeman, Jonathan E., additional, Linkermann, Andreas, additional, Liu, Jinsong, additional, Lo, Simon, additional, Locasale, Jason W., additional, Loprinzi, Charles L., additional, Lowery, Maeve, additional, Ludwig, Emmy, additional, Lunning, Matthew A., additional, Lustig, Robert A., additional, Machtay, Mitchell, additional, Mackall, Crystal, additional, Mahvi, David A., additional, Mahvi, David M., additional, Maity, Amit, additional, Majithia, Neil, additional, Malumbres, Marcos, additional, Maresso, Karen Colbert, additional, Martin, John D., additional, Matsuo, Koji, additional, Matthews, Natalie H., additional, Mauro, Lauren, additional, Mayer, R. Samuel, additional, McCaskill-Stevens, Worta, additional, McNamara, Megan A., additional, Mehta-Shah, Neha, additional, Merritt, Robert E., additional, Milowsky, Matthew I., additional, Minasian, Lori M., additional, Mitchell, Tara C., additional, Mitsis, Demytra, additional, Mollica, Michelle, additional, Mooney, Margaret, additional, Moustafa, Farah, additional, Nabati, Lida, additional, Naidoo, Jarushka, additional, Narang, Amol, additional, Nelson, Heidi, additional, Nelson, William G., additional, Nesbit, Suzanne, additional, Niglas, Mark, additional, O'Connor, Tracey, additional, Offit, Kenneth, additional, Onciu, Mihaela, additional, O’Reilly, Eileen M., additional, Ostrander, Elaine A., additional, Pappas-Taffer, Lisa, additional, Pardoll, Drew, additional, Park, Jae H., additional, Patel, Anery, additional, Patel, Anish J., additional, Patierno, Steven R., additional, Pavletic, Steven Z., additional, Phillips, Peter C., additional, Post, Miriam D., additional, Pruitt, Amy A., additional, Querfeld, Christiane, additional, Rabius, Vance A., additional, Rajkumar, S. Vincent, additional, Ramadan, Mohammad O., additional, Rankin, Erinn B., additional, Reddy, Sushanth, additional, Reid, Michael A., additional, Reznik, Scott, additional, Rizack, Tina, additional, Robinson, Jason D., additional, Robinson-Bostom, Leslie, additional, Rodriguez-Galindo, Carlos, additional, Romesser, Paul B., additional, Rosen, Steven T., additional, Rosenfeld, Myrna R., additional, Rosenthal, Nadia, additional, Ross, Meredith, additional, Rowland, Julia H., additional, Russell, Anthony H., additional, Sabel, Michael S., additional, Sahgal, Arjun, additional, Salinas, Ryan D., additional, Salo-Mullen, Erin E., additional, Salto-Tellez, Manuel, additional, Sanderson, Sydney M., additional, Sandlund, John T., additional, Santana, Victor M., additional, Savage, Michelle, additional, Schreiber, Eric C., additional, Schuchter, Lynn, additional, Schultz, Liora, additional, Seiden, Michael V., additional, Sellers, Morgan M., additional, Shah, Payal D., additional, Shia, Jinru, additional, Shilo, Konstantin, additional, Small, Eric, additional, Smith, Angela B., additional, Snow, Stephen N., additional, Solit, David B., additional, Sood, Anil K., additional, Soto-Perez-de-Celis, Enrique, additional, Sparano, Joseph A., additional, Spiegelman, Vladimir S., additional, Spunt, Sheri L., additional, Stadler, Zsofia K., additional, Steensma, David P., additional, Stone, Richard M., additional, Stranne, Steven Kent, additional, Stratton, Kelly, additional, Sugden, Bill, additional, Swanson, Andrew M., additional, Tallman, Martin S., additional, Talmadge, James E., additional, Teachey, David T., additional, Teba, Catalina V., additional, Tefferi, Ayalew, additional, Teh, Bin Tean, additional, Teng, Joyce M.C., additional, Tepper, Joel E., additional, Thaker, Premal H., additional, Thrift, Aaron P., additional, Tran, Arthur-Quan, additional, Triska, Grace, additional, Trump, Donald, additional, Tsai, Kenneth, additional, Tseng, Chia-Lin, additional, Tseng, Diane, additional, Van Schaeybroeck, Sandra, additional, Van Tine, Brian A., additional, Vanness, Erin R., additional, Varadhachary, Gauri, additional, Varella-Garcia, Marileila, additional, Wahl, Richard L., additional, Walsh, Michael F., additional, Wang, Thomas, additional, Weiss, Jared, additional, Weissman, Irving L., additional, Westin, Shannon N., additional, White, Jeffrey D., additional, Wilson, Richard, additional, Wong, Richard J., additional, Wood, Gary S., additional, Xu, Yaohui G., additional, Xu-Welliver, Meng, additional, Yust-Katz, Shlomit, additional, Zagar, Timothy, additional, Zeman, Elaine M., additional, Zhang, Tian, additional, and Zwiebel, James A., additional

Published
2020
Full Text
View/download PDF

24. Prostate Cancer

Author

Nelson, William G., primary, Antonarakis, Emmanuel S., additional, Carter, H. Ballentine, additional, De Marzo, Angelo M., additional, and DeWeese, Theodore L., additional

Published
2020
Full Text
View/download PDF

27. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study

Author

Sandler, Kiri A., Cook, Ryan R., Ciezki, Jay P., Ross, Ashley E., Pomerantz, Mark M., Nguyen, Paul L., Shaikh, Talha, Tran, Phuoc T., Stock, Richard G., Merrick, Gregory S., Demanes, D. Jeffrey, Spratt, Daniel E., Abu-Isa, Eyad I., Wedde, Trude B., Lilleby, Wolfgang, Krauss, Daniel J., Shaw, Grace K., Alam, Ridwan, Reddy, Chandana A., Song, Daniel Y., Klein, Eric A., Stephenson, Andrew J., Tosoian, Jeffrey J., Hegde, John V., Yoo, Sun Mi, Fiano, Ryan, D'Amico, Anthony V., Nickols, Nicholas G., Aronson, William J., Sadeghi, Ahmad, Greco, Stephen C., Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L., Reiter, Robert E., Said, Jonathan W., Steinberg, Michael L., Horwitz, Eric M., Kupelian, Patrick A., King, Christopher R., and Kishan, Amar U.

Published
2018
Full Text
View/download PDF

29. Interventional Radiation Oncology (IRO): Transition of a magnetic resonance simulator to a brachytherapy suite

Author

Anderson, Roberta, Armour, Elwood, Beeckler, Courtney, Briner, Valerie, Choflet, Amanda, Cox, Andrea, Fader, Amanda N., Hannah, Marie N., Hobbs, Robert, Huang, Ellen, Kiely, Marilyn, Lee, Junghoon, Morcos, Marc, McMillan, Paige E., Miller, Dave, Ng, Sook Kien, Prasad, Rashmi, Souranis, Annette, Thomsen, Robert, DeWeese, Theodore L., and Viswanathan, Akila N.

Published
2018
Full Text
View/download PDF

31. A Novel Absorbable Radiopaque Hydrogel Spacer to Separate the Head of the Pancreas and Duodenum in Radiation Therapy for Pancreatic Cancer

Author

Rao, Avani D., Feng, Ziwei, Shin, Eun Ji, He, Jin, Waters, Kevin M., Coquia, Stephanie, DeJong, Robert, Rosati, Lauren M., Su, Lin, Li, Dengwang, Jackson, Juan, Clark, Stephen, Schultz, Jeffrey, Hutchings, Danielle, Kim, Seong-Hun, Hruban, Ralph H., DeWeese, Theodore L., Wong, John, Narang, Amol, Herman, Joseph M., and Ding, Kai

Published
2017
Full Text
View/download PDF

34. Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers

Author

Antonarakis, Emmanuel S, Heath, Elisabeth I, Walczak, Janet R, Nelson, William G, Fedor, Helen, De Marzo, Angelo M, Zahurak, Marianna L, Piantadosi, Steven, Dannenberg, Andrew J, Gurganus, Robin T, Baker, Sharyn D, Parnes, Howard L, DeWeese, Theodore L, Partin, Alan W, and Carducci, Michael A

Subjects
Clinical Research, Prevention, Aging, Clinical Trials and Supportive Activities, Cancer, Urologic Diseases, Prostate Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Biomarkers, Tumor, Celecoxib, Cyclooxygenase Inhibitors, Double-Blind Method, Humans, Male, Middle Aged, Neoadjuvant Therapy, Prostate, Prostatic Neoplasms, Pyrazoles, Sulfonamides, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeCyclooxygenase-2 (COX-2) is a potential pharmacologic target for the prevention of various malignancies, including prostate cancer. We conducted a randomized, double-blind trial to examine the effect of celecoxib on drug-specific biomarkers from prostate tissue obtained at prostatectomy.Patients and methodsPatients with localized prostate cancer and Gleason sum > or = 7, prostate-specific antigen (PSA) > or = 15 ng/mL, clinical stage T2b or greater, or any combination with greater than 45% risk of capsular penetration were randomly assigned to celecoxib 400 mg by mouth twice daily or placebo for 4 to 6 weeks before prostatectomy. The primary end point was the difference in prostatic prostaglandin levels between the two groups. Secondary end points were differences in COX-1 and -2 expressions; oxidized DNA bases; and markers of proliferation, apoptosis and angiogenesis. Tissue celecoxib concentrations also were measured. Tertiary end points were drug safety and compliance.ResultsSeventy-three patients consented, and 64 were randomly assigned and included in the intention-to-treat analysis. There were no treatment differences in any of the primary or secondary outcomes. Multivariable regression revealed that tumor tissue had significantly lower COX-2 expression than benign prostatic tissue (P = .01) and significantly higher levels of the proliferation marker Ki-67 (P < .0001). Celecoxib was measurable in prostate tissue of patients on treatment, demonstrating that celecoxib reached its target. Celecoxib was safe and resulted in only grade 1 toxicities.ConclusionTreatment with 4 to 6 weeks of celecoxib had no effect on intermediate biomarkers of prostate carcinogenesis, despite the achievement of measurable tissue levels. We caution against using celecoxib 400 mg twice daily as a preventive agent for prostate cancer in additional studies.

Published
2009

36. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

Author

Hasan, Hamza, Deek, Matthew P., Phillips, Ryan, Hobbs, Robert F., Malek, Reem, Radwan, Noura, Kiess, Ana P., Dipasquale, Shirl, Huang, James, Caldwell, Terry, Leitzel, Jessica, Wendler, Danielle, Wang, Hao, Thompson, Elizabeth, Powell, Jonathan, Dudley, Sara, Deville, Curtiland, Greco, Stephen C., Song, Daniel Y., DeWeese, Theodore L., Gorin, Michael A., Rowe, Steven P., Denmeade, Sam, Markowski, Mark, Antonarakis, Emmanuel S., Carducci, Michael A., Eisenberger, Mario A., Pomper, Martin G., Pienta, Kenneth J., Paller, Channing J., and Tran, Phuoc T.

Published
2020
Full Text
View/download PDF

37. Metastasis-Directed Therapy In Prostate Cancer: Why, When, and How?

Author

Phillips, Ryan M., Deek, Matthew P., DeWeese, Theodore L., and Tran, Phuoc T.

Subjects
Prostate cancer -- Development and progression, Ipilimumab -- Health aspects, Metastasis -- Development and progression, Radiation -- Health aspects, Pain -- Care and treatment, Radiotherapy -- Health aspects, Health
Abstract

Metastatic prostate cancer remains a life-limiting disease; while we have seen significant advances in systemic approaches which form the backbone of management, no curative paradigm yet exists. Metastasis-directed therapy (MDT) with stereotactic ablative radiotherapy (SABR) has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer. Herein we will review the rationale, potential benefits, and practical considerations associated with this approach., Why Treat Prostate Cancer Metastases with Ablative Radiation? Rationale for Metastasis-Directed Therapy (MDT) in Prostate Cancer Traditionally, the management of metastatic cancer has been chiefly through systemic treatments (excellent summary [...]

Published
2019

45. Figure S2 from Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer

Author

Marshall, Catherine H., primary, Fu, Wei, primary, Wang, Hao, primary, Park, Jong Chul, primary, DeWeese, Theodore L., primary, Tran, Phuoc T., primary, Song, Daniel Y., primary, King, Serina, primary, Afful, Michaella, primary, Hurrelbrink, Julia, primary, Manogue, Charlotte, primary, Cotogno, Patrick, primary, Moldawer, Nancy P., primary, Barata, Pedro C., primary, Drake, Charles G., primary, Posadas, Edwin M., primary, Armstrong, Andrew J., primary, Sartor, Oliver, primary, and Antonarakis, Emmanuel S., primary

Published
2023
Full Text
View/download PDF

46. Supplemental Figures from TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis

Author

Malek, Reem, primary, Gajula, Rajendra P., primary, Williams, Russell D., primary, Nghiem, Belinda, primary, Simons, Brian W., primary, Nugent, Katriana, primary, Wang, Hailun, primary, Taparra, Kekoa, primary, Lemtiri-Chlieh, Ghali, primary, Yoon, Arum R., primary, True, Lawrence, primary, An, Steven S., primary, DeWeese, Theodore L., primary, Ross, Ashley E., primary, Schaeffer, Edward M., primary, Pienta, Kenneth J., primary, Hurley, Paula J., primary, Morrissey, Colm, primary, and Tran, Phuoc T., primary

Published
2023
Full Text
View/download PDF

47. Data from TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis

Author

Malek, Reem, primary, Gajula, Rajendra P., primary, Williams, Russell D., primary, Nghiem, Belinda, primary, Simons, Brian W., primary, Nugent, Katriana, primary, Wang, Hailun, primary, Taparra, Kekoa, primary, Lemtiri-Chlieh, Ghali, primary, Yoon, Arum R., primary, True, Lawrence, primary, An, Steven S., primary, DeWeese, Theodore L., primary, Ross, Ashley E., primary, Schaeffer, Edward M., primary, Pienta, Kenneth J., primary, Hurley, Paula J., primary, Morrissey, Colm, primary, and Tran, Phuoc T., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure Legends from Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation

Author

Hedayati, Mohammad, primary, Haffner, Michael C., primary, Coulter, Jonathan B., primary, Raval, Raju R., primary, Zhang, Yonggang, primary, Zhou, Haoming, primary, Mian, Omar, primary, Knight, Emma J., primary, Razavi, Nina, primary, Dalrymple, Susan, primary, Isaacs, John T., primary, Santos, Aileen, primary, Hales, Russell, primary, Nelson, William G., primary, Yegnasubramanian, Srinivasan, primary, and DeWeese, Theodore L., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 3 from Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation

Author

Hedayati, Mohammad, primary, Haffner, Michael C., primary, Coulter, Jonathan B., primary, Raval, Raju R., primary, Zhang, Yonggang, primary, Zhou, Haoming, primary, Mian, Omar, primary, Knight, Emma J., primary, Razavi, Nina, primary, Dalrymple, Susan, primary, Isaacs, John T., primary, Santos, Aileen, primary, Hales, Russell, primary, Nelson, William G., primary, Yegnasubramanian, Srinivasan, primary, and DeWeese, Theodore L., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Data from Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer

Author

Marshall, Catherine H., primary, Fu, Wei, primary, Wang, Hao, primary, Park, Jong Chul, primary, DeWeese, Theodore L., primary, Tran, Phuoc T., primary, Song, Daniel Y., primary, King, Serina, primary, Afful, Michaella, primary, Hurrelbrink, Julia, primary, Manogue, Charlotte, primary, Cotogno, Patrick, primary, Moldawer, Nancy P., primary, Barata, Pedro C., primary, Drake, Charles G., primary, Posadas, Edwin M., primary, Armstrong, Andrew J., primary, Sartor, Oliver, primary, and Antonarakis, Emmanuel S., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results